Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What would be your percutaneous approach to a severely stenotic bifurcation lesion with a large aneurysm post-stenosis?
Related Questions
Would you favor culprit-only PCI, complete revascularization via percutaneous approach, or urgent CABG evaluation for a young diabetic patient with newly reduced LVEF < 35% presenting with an anterior STEMI and multivessel disease?
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?
Should CYP2C19 genotype testing be performed in patients presenting with ISR on Plavix?
In a patient with IABP set on 1:1, do you always maintain them on systemic heparin, and if so, is there a goal ACT range?
Do you favor ticagrelor or prasugrel first-line for the treatment of ACS with planned PCI, provided no contraindications to either agent?
Would you continue SAPT beyond 12 months after left main stenting in an elderly patient on DOAC for paroxysmal atrial fibrillation?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
When is a reasonable amount of time for patients to be on 90 mg BID of ticagrelor before transitioning to 60 mg BID following PCI?
